We have examined the presence of p16 MTS1/CDK4I gene deletions, mutations and methylation status, and 9p21-23 deletions in a series of 46 squamous cell carcinomas of the larynx and paired normal mucosa previously characterized for cyclin D1 gene ampli®cation and overexpression. pRb expression was also examined by immunohistochemistry. p16 MTS1/CDK4I mutations were found in 10/46 (22%) carcinomas and hypermethylation in 2/31 (7%). Loss of heterozygosity at 9p21-23 was found in 24 out of 42 (57%) carcinomas examined. All p16 MTS1/CDK4I mutated cases and the two hypermethylated carcinomas showed 9p21-23 loss of heterozygosity. The loss of heterozygosity correlated with advanced local invasion (P=0.0045), lymph node metastases (P=0.0326), stage IV of the tumors (P=0.0058), and existence of cyclin D1 ampli®cation/overexpression (P<0.03). Only one out of 37 carcinomas was negative for pRb expression. No alterations in p16 gene or 9p21-23 loss of heterozygosity were detected in this case. These ®ndings indicate that p16 MTS1/CDK4I is frequently inactivated by gene mutation, hypermethylation, and allelic deletions in a signi®cant subset of squamous cell carcinomas of larynx. Since 9p21-23 loss of heterozygosity was more frequently detected than p16 MTS1/CDK4I mutations, and mutated carcinomas invariably had loss of heterozygosity, allelic losses probably precede the p16 MTS1/CDK4I mutations. Their association with cyclin D1 deregulation in advanced carcinomas could indicate a possible cooperative eect in the progression of these neoplasms.
We have examined the presence of p16 MTS1/CDK4I gene deletions, mutations and methylation status, and 9p21-23 deletions in a series of 46 squamous cell carcinomas of the larynx and paired normal mucosa previously characterized for cyclin D1 gene ampli®cation and overexpression. pRb expression was also examined by immunohistochemistry. p16 MTS1/CDK4I mutations were found in 10/46 (22%) carcinomas and hypermethylation in 2/31 (7%). Loss of heterozygosity at 9p21-23 was found in 24 out of 42 (57%) carcinomas examined. All p16 MTS1/CDK4I mutated cases and the two hypermethylated carcinomas showed 9p21-23 loss of heterozygosity. The loss of heterozygosity correlated with advanced local invasion (P=0.0045), lymph node metastases (P=0.0326), stage IV of the tumors (P=0.0058), and existence of cyclin D1 ampli®cation/overexpression (P<0.03). Only one out of 37 carcinomas was negative for pRb expression. No alterations in p16 gene or 9p21-23 loss of heterozygosity were detected in this case. These ®ndings indicate that p16 MTS1/CDK4I is frequently inactivated by gene mutation, hypermethylation, and allelic deletions in a signi®cant subset of squamous cell carcinomas of larynx. Since 9p21-23 loss of heterozygosity was more frequently detected than p16 MTS1/CDK4I Introduction Squamous cell carcinoma (SCC) of the larynx is an aggressive malignant neoplasm which is relatively frequent in certain countries (Tuyns et al., 1988) . The molecular alterations leading to the development and progression of these carcinomas remain unclear. Several genetic studies have identi®ed p53 gene mutations and protein overexpression as early events in the development of SCC of the upper respiratory tract and lung (Dolcetti et al., 1992; Nadal et al., 1995) . Additionally, we and others have recently shown that deregulation of cyclin D1 by gene ampli®cation and overexpression is associated with advanced stages and poor prognostic evolution of laryngeal carcinomas (Jares et al., 1994; Meredith et al., 1995; Michalides et al., 1995) .
Cytogenetic studies of head and neck carcinomas have shown frequent 9p deletions . The p16 MTS1/CDK4I gene, a member of the ink-4 inhibitor kinase family, has been mapped to the 9p21 region and it has been suggested as a putative tumor suppressor gene implicated in these deletions. p16
MTS1/CDK4I binds to CDK4 and inhibits the catalytic activity of the CDK4/cyclin D1 complexes (Serrano et al., 1993) . The inactivation of p16 MTS1/CDK4I seems to cooperate with cyclin D1 in the deregulation of cell cycle progression in tumor cells with normal pRb function (Lukas et al., 1995) . The p16 MTS1/CDK4I gene has been found to be deleted, mutated, or downregulated by hypermethylation in dierent types of tumors including SCC cell lines and tumors of dierent localizations (Caldas et al., 1994; Hayashi et al., 1994; Kamb et al., 1994; Merlo et al., 1995; Mori et al., 1994; Nobori et al., 1994; Okamoto et al., 1994; Zhou et al., 1994) . However, mutations of p16 MTS1/CDK4I have rarely been found in primary tumors with 9p hemizygous deletion (Cairns et al., 1994; Shimizu and Sekiya, 1995; Spruck et al., 1994) .
To determine the possible role of p16 MTS1/CDK4I alterations in the development and progression of SCC of the larynx as well as its possible cooperation with cyclin D1 gene abnormalities, we have examined the presence of p16 MTS1/CDK4I gene deletions, mutations, and methylation status, and 9p21-23 deletions in a series of laryngeal carcinomas previously characterized for cyclin D1 gene ampli®cation and overexpression.
Results

p16
MTS1/CDK4I gene mutations A series of 46 human squamous cell carcinomas (SCC) of the larynx and their respective normal tissues was analysed for the presence of p16 MTS1/CDK4I gene mutations in exons 1 and 2 using PCR ± SSCP and sequencing analyses. A total of 10 somatic mutations were detected in 10 tumors (22%), nine were present in exon 2 and one in exon 1 (Table 1 ). In addition, two cases showed the previously described polymorphism in codon 148 (CGA?GGA). Examples of SSCP and DNA sequencing of the p16 MTS1/CDK4I gene are shown in Figures 1 and 2 .
Four cases had frameshift mutations due to microdeletions of 1 bp, 2 bp, or insertion of two base pairs, all of them occurring in the ankyrin repeat motif. One of the two cases showing a 1 bp microdeletion (case 102) had a complex mutation because, in addition to the microdeletion at codon 55, it had a missense mutation at codon 54 (ATG?ATA) determining the change of Met by Ile. According to the sequencing and LOH studies, the two mutations seemed to be in the same allele. The other 1 bp microdeletion (case 223) occurred at codon 56. The two remaining frameshift mutations were a 2 bp microdeletion at codon 35 (case 96) and a 2 bp insertion occurring at codon 57 (case 235).
One case (case 105) had a missense mutation in the region of the four ankyrin consensus repeats of the p16 MTS1/CDK4I amino acid sequence. This mutation involved codon 84 (GAC?TAC), resulting in a change of aspartic by tyrosine that seems to aect the binding of p16 to CDK4 (Yang et al., 1996) . Two tumors showed non-sense mutations, one at codon 88 GAG?TAG (Glu?Stop) (case 110) and the other (case 398) at codon 58 CGA?TGA (Arg?Stop). Another case (case 221) had a 3 bp in-frame microdeletion resulting in the loss of one of three leucines present at codons 62 to 64. Alterations in these residues have also been reported to aect strongly the binding of p16 to CDK4 (Yang et al., 1996) . Finally, two cases (cases 84 and 406) showed the same change of guanine to adenine in the 71 position of the 3' splicing acceptor signal of exon 2. This guanidine is part of the splice junction sequences that is highly conserved in eukariotic genes. This change aects the normal processing of mRNA and could lead to the synthesis of an aberrant p16 mRNA.
The correlation between p16 MTS1/CDK4I mutations and the clinical and pathological characteristics of the patients is summarized in Table 2 . The two grade IV carcinomas had p16 MTS1/CDK4I mutation (P50.05). Mutated tumors were more frequently associated with advanced stage (stage IV), extensive local invasion, and lymph node metastases. However, these dierences did not reach statistical signi®cance. No correlation was observed between the existence of p16 MTS1/CDK4I mutation and the age of the patients, localization of the tumors, keratinization or cyclin D1 ampli®cation or overexpression (Tables 2 and 3 ).
MTS1/CDK4I gene deletions and loss of heterozygosity (LOH) at 9p21-23
The presence of possible p16 MTS1/CDK4I gene deletions was analysed by Southern blot in 30 laryngeal carcinomas and their respective normal mucosa. No homozygous deletions or rearrangements of the gene were found. However, in seven cases (23%) the tumor sample showed a 30 ± 50% reduction in the hybridization signal in comparison with the respective normal tissue, suggesting a possible heterozygous allelic loss of the gene (data not shown).
Loss of heterozygosity (LOH) was examined in 42 carcinomas and matched normal tissue using PCR ampli®cation of four microsatellites encompassing loci at 9p21-p23. To avoid DNA contamination from normal tissue surrounding the tumor cells, we used a microdissection technique of frozen tissue sections (Emmert-Buck et al., 1994). DNA for PCR amplification was extracted from tumor cells microdissected Figure 1 SSCP analysis of p16 MTS-1/CDK4I gene, exon 2. Lane numbers correspond to ®ve tumors and normal matched tissue with a mobility shift alteration. Exon 2 was ampli®ed and digested with SmaI restriction enzyme before being run in a nondenaturing 15% polyacrylamide gel p16 MTS1/CDK4I in laryngeal carcinomas P Jares et al under direct microscopic visualization. One p16 mutated case was not studied due to a lack of DNA from normal tissue. All cases were informative at, at least one locus. LOH was detected in the nine tumors with p16 mutation (100%) (Figure 3 ). All showed LOH at two or more of the four loci analysed (Figure 4) . In four tumors with p16 MTS1/CDK4I mutation (cases 398, 105, 102, 84) , the LOH included the D9S171 and IFNA loci suggesting the loss of p16 MTS1/CDK4I locus. In three other mutated tumors (cases 110, 221, and 223) the LOH was detected at D9S161 and D9S171 loci, whereas the 21 (84) 15 (71) 4 (16) 6 (29) 22 20 14 (64) 4 (20) 8 ( 24 (83) 12 (71) 5 (17) 5 (29) 24 18 15 (63) 3 (17) 9(37) 15 (83) c Lymph node metastases 7 + 36 10
30 (83) 6 (60) 6 (17) 4 (40) 33 9 17 (52) 1 (11) 16 (47) Table 3 Correlation between p16 MTS1/CDK4I mutation and 9p21-23 loss of heterozygosity and cyclin D1 alterations 24 (83) 12 (71) 24 (80) 11 (73) 5 (17) 5 (29) 6 (20) 4 (27) 26 16 28 14 15 (58) 3(19) 16 (57) 2 (14) 11 (42) 13 (81 p16 MTS1/CDK4I in laryngeal carcinomas P Jares et al IFNA locus was not informative and the heterozygosity was retained at D9S157. D9S161 and D9S157 loci were lost in case 96 and the other two loci were not informative. In the remaining mutated case (case 235), LOH was detected at D9S157 and D9S171 loci, not being informative at the IFNA locus and retaining both alleles at D9S161. Therefore, loss of the p16 MTS1/CDK4I locus in these tumors can not be de®nitively con®rmed, but we could de®ne a minimal common area of loss between D9S171 and IFNA surrounding the p16 MTS1/CDK4I locus. LOH, in at least one of these loci, occurred in 15 cases (45%) of the 33 carcinomas without p16 MTS1/CDK4I mutations. Thus, 57% (24 out of 42) of these laryngeal carcinomas showed a LOH at 9p21-23 ( Figure 4 ). The correlation between LOH and the clinical and pathological characteristics of the patients is summarized in Table 2 . LOH was signi®cantly associated with advanced stage of the tumors, since 16 out of 20 (80%) stage IV carcinomas showed LOH and this was observed only in 8 out of 22 (36%) stage I ± III carcinomas (P=0.0058). Similarly, LOH was associated with local invasion, since 15 of the 18 (83%) carcinomas with extensive local invasion (T4 carcinomas) showed LOH, whereas it was only detected in nine out of 24 (37%) of the carcinomas with limited invasion (T1 ± T3 tumors) (P=0.0045). A signi®cant correlation was also observed between the LOH at 9p21-23 and the presence of lymph node metastases (P=0.0326). Contrarily, no association was observed between LOH and the presence of keratinization, histological grade, localization of the tumors and the age of the patients.
Cyclin D1 gene was ampli®ed in 17 out of 46 (37%) carcinomas and overexpressed in 15 out of 45 (33%). These alterations were mainly found in advanced tumors (Table 4) . Interestingly, LOH at 9p21-23 was signi®cantly associated with cyclin D1 ampli®cation and mRNA overexpression. Thirteen out of 16 (81%) tumors with cyclin D1 ampli®cation showed a LOH, while the LOH was detected in only 11 out of 26 (42%) tumors without ampli®cation (P=0.0236). Likewise, the LOH at 9p21-23 correlated with cyclin D1 overexpression, since 86% of the tumors with cyclin D1 overexpression had LOH compared to 43% of the tumors without overexpression (P=0.0206) ( MTS-1/CDK4I mutation. Cases 221 and 223 showed LOH at two loci, D9S161 and D9S171. They were noninformative for IFNA loci and retained heterozygosity at D9S157. Case 96 showed LOH at D9S161 and D9S157, but it was not informative at either D9S171 or at IFNA Figure 4 Patterns of chromosome 9p21-23 loss in SCC of larynx. Markers are listed in order according to the sex average genetic map (Kwiatowski et al., 1993) . The localization of p16
is indicated with a vertical arrow (;). All mutated cases showed loss of heterozygosity at at least two loci. Fifteen cases without p16 MTS-1/CDK4I mutation showed LOH at at least one locus. NI: non-informative . Dierent samples of normal laryngeal tissues from these patients were used as control of nonmethylated status and all of them showed the expected non-methylated pattern of bands. However, two of the 14 carcinomas (14%) with 9p21-23 LOH showed hypermethylation at exon 1 of p16 gene MTS1/CDK4I
( Figure 5 ). One case was at an early stage of dissemination (Stage I) but the other was an advanced carcinoma (Stage IV). No Cyclin D1 gene ampli®cation or mRNA overexpression were detected in any of these two carcinomas. No hypermethylation was observed in any of the 17 carcinomas without 9p21-23 alterations.
Retinoblastoma expression
Retinoblastoma seems to participate in the same regulatory pathway as p16 MTS1/CDK4I and cyclin D1 (Serrano et al., 1993; Lukas et al., 1995) . Several studies have observed an inverse correlation between alterations of both genes in mutually exclusive subsets of tumors (Shapiro et al., 1995; Ueki et al., 1996) . To assess the possible alterations in pRb expression in this series of laryngeal carcinomas we have examined immunohistochemically 37 cases, nine with p16 MTS1/CDK4I mutations and 9p21-23 LOH, 13 with only 9p21-23 LOH, and 15 with no genetic alterations in these regions. Only one of the 37 carcinomas (3%) was negative for pRB expression. No p16 alterations, 9p21-23 deletions, or cyclin D1 ampli®cation/overexpression were found in this particular case. This tumor was in Stage III (T 3 , N 0 ). In the remaining cases the presence of retinoblastoma protein was observed diusely in all the tumor areas. The number of positive cells was variable from case to case but usually more than 25% of the tumor cells were positive in all cases.
Discussion
In this study we have examined a series of 46 human squamous cell carcinomas (SCC) of the larynx for the presence of deletions, hypermethylation, and mutations of the p16 MTS1/CDK4I gene. Somatic mutations were detected in 10 out of 46 (22%) carcinomas and hypermethylation in two out of 31 (7%) tumors examined. All the informative mutated cases and the two hypermethylated showed LOH at 9p21-23. In addition, LOH was also found in 42% of the carcinomas without p16 MTS1/CDK4I mutations or hypermethylation. In this series, LOH at 9p21-23 was associated with aggressive tumors showing extensive local invasion, presence of lymph node metastases, and advanced stage of dissemination.
The prevalence of p16 MTS1/CDK4I mutations in this series of laryngeal carcinomas (22%) is similar to the 27% observed in SCC of the lung (Hayashi et al., 1994) and higher than the 7 ± 10% detected in other head and neck carcinomas (Zhang et al., 1994) . However, this prevalence is still lower than the 44% of mutations observed in SCC cell lines (Zhang et al., 1994) . The p16 MTS1/CDK4I mutations detected in our study were clearly disruptive of the gene structure (two stop codons, four frameshifts and two aberrant splicings) or function (two mutations involving important residues for the binding to CDK4). The spectrum of these mutations is similar to that observed in other solid tumors including pancreas, lung, esophageal SCC, and bladder carcinomas (Caldas et al., 1994; Hayashi et al., 1994; Mori et al., 1994) . Frameshift mutations have not been detected in two previous studies on head and neck carcinomas (Cairns et al., 1994; Zhang et al., 1994) . However, SCC of the lung and esophagus show a similar incidence of these mutations, 55% and 57% respectively, to that seen in our study (40%) (Hayashi et al., 1994; Mori et al., 1994) .
To our knowledge, the frameshift mutations occurring at codon 56, 35, and 57 in this series have not been previously described. In addition, the two mutations at the last base of intron 1 and the nonsense mutation at codon 88 observed in our tumors have only been reported in one nasopharngeal carcinoma and melanoma cell line, respectively, but not in primary tumors (Lo et al., 1995; Pollock et al., 1995) .
All laryngeal carcinomas with p16 MTS1/CDK4I mutations in our series showed LOH in at least two polymorphic markers surrounding p16 MTS1/CDK4I gene at 9p21-23. All informative cases had LOH at D9S171, the closest microsatellite marker to p16 locus. The consistent coincidence of p16 MTS1/CDK4I mutation and LOH at 9p21 -23 suggest that p16 MTS1/CDK4I might act as a tumor suppressor gene in laryngeal carcinomas, suering inactivation by gene mutation of one allele and allelic loss of the other. Similarly, Zhou et al. have reported coincidence in p16 MTS1/CDK4I mutations and LOH at 9p21-23 in ®ve out of 43 esophageal carcinomas (Zhou et al., 1994) . Since 9p21-23 LOH was more frequently detected than the p16 MTS1/CDK4I mutation and mutated carcinomas invariably had LOH, allelic losses probably precede p16 MTS1/CDK4I mutations in the development of these tumors.
LOH at the 9p21-23 region was also detected in 42% of these carcinomas without p16 MTS1/CDK4I alterations. The implication of 9p deletions in the progression of head and neck tumors was suggested before the mapping of p16 MTS1/CDK4I to this chromosome. Several MTS1/CDK4I in laryngeal carcinomas P Jares et al cytogenetic and microsatellite studies had detected 9p allelic losses in 40 ± 72% of head and neck tumors with a minimal common region around 9p21 Van Dyke et al., 1994) . More recently, LOH at 9p21 has also been detected in preinvasive lesions of head and neck tumors and premalignant lesions of oral mucosa suggesting that this genetic alteration is an early event in the progression of SCC of this region (Mao et al., 1996; . In our study, we found LOH at 9p21-23 in 36% carcinomas in early stages. However, LOH was signi®cantly more frequent (80%) in advanced carcinomas with extensive local invasion and lymph node metastases suggesting that allelic losses at 9p21-23 may be clonally selected and may favor the progression of these tumors.
How allelic losses at 9p21-23 may facilitate the progression of these carcinomas is not clear. p16
MTS1/CDK4I mutations were found in 36% of the deleted tumors suggesting the inactivation of both p16 MTS1/CDK4I alleles. The remaining allele of p16
may also be inactivated by other mechanisms such as microdeletions, and hypermethylation or mutation of its promoter region. Hypermethylation of the p16 MTS1/CDK4I promoter has been described in dierent tumors, including occasional head and neck carcinomas, and it has been associated with the loss of p16 MTS1/CDK4I mRNA expression . In our study, we found hypermethylation of exon 1 in two out of 31 (7%) carcinomas and both cases had LOH at 9p21-23, suggesting inactivation of both p16 alleles. Several studies have suggested that p16 MTS1/CDK4I may not be the only or primary target of inactivation in this chromosomal region, and that other tumor suppressor genes could also be implicated (Neville et al., 1995; Puig et al., 1995) . However, the relatively high number of cases with p16 MTS1/CDK4I inactivation by mutations and hypermethylation observed in our study and the constant association of these alterations with 9p21-23 allelic losses strongly suggest that this gene is the main target in at least a signi®cant subset of laryngeal squamous cell carcinomas.
This series of laryngeal carcinomas had been previously examined for the ampli®cation and overexpression of cyclin D1 gene. These alterations were found to be signi®cantly associated with carcinomas in advanced stage of dissemination (Jares et al., 1994) . We have now found a signi®cant correlation between the 9p21-23 LOH and the ampli®cation and overexpression of the cyclin D1 gene (Table 3) . Cyclin D1 may function as an oncogene in dierent models but its tumorigenic and transforming properites seem to be less eective than conventional oncogenes (Hinds et al., 1994; Lovec et al., 1994) . p16 MTS1/CDK4I and cyclin D1 participate in the same cell cycle regulatory pathway also involving CDK4 and retinoblastoma (Lukas et al., 1994 (Lukas et al., , 1995 Medema et al., 1995; Tam et al., 1994) . In vitro studies have indicated that inactivation of p16 MTS1/CDK4I and overexpression of cyclin D1 cooperate synergistically to deregulate cell proliferation in cell lines with normal pRb function (Lukas et al., 1995) . Our observations in this series of laryngeal carcinomas suggest that deregulation of cyclin D1 gene may have an additional oncogenic eect conferring a selective growth advantage to cells with 9p21-23 allelic losses. Alterations in 9p21-23 region and p16 MTS1/CDK4I gene seem also to precede cyclin D1 overexpression in these tumors since cyclin D1 overexpression was only seen in advanced stage III and IV carcinomas (Tables 2 and 4) .
Retinoblastoma gene product is considered a downstream target of the cyclin D/CDK4-6 complexes. Alterations of cyclin D1 or p16 MTS1/CDK4I genes have been usually observed in tumors with normal pRb. On the contrary, pRb inactivation seem to occur mainly in tumors with no alterations in cyclin D1 or p16
genes (Jiang et al., 1993; Schauer et al., 1994; Ueki et al., 1996) . These observations suggest that inactivation of any of these regulatory elements may be important in the pathogenesis of certain tumors. In laryngeal SCC, inactivation of pRb gene seems to be an unfrequent phenomenon since it was only seen in one case of our series. However, no alterations of the p16 MTS1/CDK4I or cyclin D1 genes were observed in this particular case. Therefore, in this study we found an alteration in at least one element of the pRb/cyclin D1/ p16 MTS1/CDK4I pathway in 21 out of the 37 (57%) carcinomas in which all three elements had been examined. Thus, cyclin D1 overexpression was found in 12 carcinomas, p16 MTS1/CDK4I mutations with 9p21-23 LOH in nine tumors (three of them also had cyclin D1 overexpression), two carcinomas showed p16 MTS1/CDK4I hypermethylation with 9p21-23 LOH, and one case had loss of pRb. These ®nding suggest that alterations in this cell cycle regulatory pathway participate in the pathogenesis of a signi®cant number of laryngeal carcinomas.
In conclusion, our study indicates that p16
gene mutations are a relatively frequent phenomenon in laryngeal carcinomas, and are constantly associated with 9p21-23 LOH. Inactivation of this gene by hypermethylation also occurs in these tumors but in a lower number of cases. The higher frequency of 9p21-23 LOH than p16 MTS1/CDK4I mutations and hypermethylations, and the event that these alterations are invariably associated with LOH suggest that allelic losses probably precede p16
MTS-1/CDK4I mutation and hypermethylation of the gene. The signi®cant correlation between 9p21-23 LOH and the ampli®cation and overexpression of cyclin D1 in more advanced tumors suggest a possible cooperative eect in the progression of these tumors.
Materials and methods
Patients and tissues
A series of 46 human squamous cell carcinomas (SCC) of the larynx was obtained from the ®les of the Pathology 
DNA extraction, Southern-blot and Methylation analysis
Genomic DNA was extracted from frozen tissue of tumors and matched normal mucosas using proteinase K/RNAse treatment and phenol-chloroform extraction (Sambrook et al., 1989) . Ten mg of high-molecular-weight DNA, isolated from frozen tissue of 30 carcinomas and matched normal mucosas, were digested with EcoRI. The samples were separated on 0.8% agarose gels and transferred to Hybond-N membranes (Amersham Int, Amersham, UK). The membranes were prehybridized, hybridized with a p16
exon 2 probe and washed as previously described (Jares et al., 1994) . To normalize the loading, the blots were hybridized with a Beta-actin probe, after stripping o the p16 MTS1/CDK4I probe. To evaluate the intensity of the signals of the Southern blot analysis, the autoradiographic signals were quanti®ed using a UVP-500 video densitometer (UVP, San Gabriel, CA). Probes were radiolabeled with a random primer DNA-labeling kit (Promega Corp., Madison, WI) with [a-32 P]dCTP. Exon 2 p16 MTS1/CDK4I probe was obtained by PCR, using the primers and the same conditions described above. The PCR product was cloned using the TA Cloning KIT (Invitrogen Co,) and sequenced to con®rm its speci®city.
To assess the methylation state of exon 1 of the p16 MTS1/CDK4I gene, 15 mg of genomic DNA were ®rst digested with 20 units of SmaI or 10 units of SacII per mg of DNA overnight. The restriction digests were ethanol precipitated and further digested with EcoRI . Restricted DNA was fractioned on a 0.8% agarose gel and transferred to Hybond membranes, and hybridized with an exon 1 probe as described. The exon 1 probe was generated by PCR using primers and conditions previously described (Pinyol et al., 1997) .
Single stranded conformation polymorphism (SSCP) analysis SSCP analysis was used to screen for p16 MTS1/CDK4I gene mutations in exons 1 and 2, which include 98% of the coding sequence, according to a modi®ed protocol of a previously described method (Orita et al., 1989) . Exons 1 and 2 were ampli®ed by PCR using a single set of¯anking intronic primers. Primers for exon 1 were: 5'-GAAGAAA-GAGGAGGGGCTG-3' and 5'-GCGCTACCTGATTCCA-ATTC-3' and primers for exon 2 were 5'-CTCTAC-ACAAGCTTCCTTTCC-3' and 5'-GGGCTGAACTTTC-TGTGCTGG-3'. Ampli®cations were performed with 0.2 mg of genomic DNA, 2.5 U Taq polymerase (Gibco-BRL), 0.5 mmol/L of each primer, 100 mmol/L of dNTPs, 5% Dimethyl Sulfoxide, and PCR buer in a ®nal volume of 50 mL. We used a modi®cation of the touchdown PCR strategy (stepdown PCR) (Hecker and Kenneth 1996) . Conditions were one step at 958C for 5 min, four cycles at 948C for 45 s, at 688C for 1 min, and at 728C for 1 min; four cycles with annealing at 648C, four cycles with annealing at 628C and 30 cycles with annealing at 608C. PCR products of both exons were digested with SmaI, diluted ®vefold in formamide-dye loading buer, incubated for 3' at 958C, and immediately cooled on ice. Twenty ml were loaded on a 15% non-denaturing polyacrylamide gel with or without 10% glycerol, and electrophoresed at 150 V for 14 h at room temperature. The gels were developed using a previously described silver staining procedure (Oto et al., 1993) .
DNA sequencing
PCR products with altered migration were puri®ed and sequenced using a commercial cycle sequencing kit (AmpliCycle, Perkin Elmer) and [a- 33 P]dATP. A total of 0.5 ml of the p16 MTS1/CDK4I gene PCR products was used as a template for sequencing. The primers described above and two internal primers for exon 2, 5'-ACTCTCACCC-GACCCGTGCA-3' and 5'-AGCTCCTCAGCCAGGTC-CA-3' were used for the sequencing reaction at a ®nal concentration of 0.5 mM. The reaction was performed according to the instructions supplied by the manufacturer. The conditions of the ampli®cation reaction for exon 2 were 30 cycles at 948C for 30 s and 708C for 30 s. Exon 1 was sequenced using the primers described above. The reaction conditions for exon 1 were 30 cycles at 948C for 30 s, 428C for 30 s and 708C for 1 min. The ®nal volume was diluted twofold in formamide-dye loading buer. Samples were denatured for 3' at 958C and 2 ml were analysed in a denaturing 6% polyacrylamide/8M urea sequencing gel for 2 or 3 h at 55W. The gels were dried under vacuum at 858C and exposed to a X-ray ®lm at room temperature, for 3 days without intensifying screen. The presence of a mutation was con®rmed by sequencing the other DNA strand.
Microsatellite analysis
LOH studies were performed by PCR ampli®cation of four highly polymorphic microsatellite markers from the region 9p21-23. Primer information for the four markers (D9S157, D9S171, IFNA and D9S161) was obtained from the GeÂ neÂ thon collection of microsatellite markers (Gyapay et al., 1994) . The DNA used for microsatellites analysis was extracted from microdissected tissue obtained from 10 micrometer frozen sections. The microdissections were performed with the tip of a sterilized toothpick under direct microscopic examination (Emmert-Buck et al., 1994) . Afterwards, they were subjected to digestion with a lysis buer (10 mM Tris-HCl pH=7.4, 1 mM EDTA pH=8, 0.5% Tween-20 and proteinase K 300 mg/ml) and phenol chloroform extraction (Sambrook et al. 1989 ) to isolate DNA. All PCRs of microsatellite sequences were carried out in a total volume of 25 ml containing 100 ng of normal genomic DNA of 2 ml of microdissection-obtained tumor DNA, 2.5 U Taq polymerase (Gibco-BRL), 0.5 mm/ L of each primer, 100 mmol/L of dNTPs, 5% Dimethyl Sulfoxide and PCR buer. Ampli®ciations of each primer set were performed using a modi®cation form of the touchdown PCR (stepdown PCR). Conditions were: 958C for 5 min, two cycles with denaturation at 958C for 45 s, annealing at 668C for 1 min and extension at 708C for 1 min, two cycles with annealing at 648C, two cycles with annealing at 628C, two cycles with annealing at 608C and 23 cycles with annealing temperature at 588C. PCR products were diluted twofold in loading buer, denatured 5 min at 908C and 5 ml were electrophoresed in a denaturing 6% polyacrylamide/8M urea sequencing gel at 55W and silver stained. In informative cases, if one allele was signi®cantly decreased in tumor DNA, relative to normal DNA (more than 50%) was scored as LOH. To con®rm the results, LOH assays were repeated at least twice.
Immunohistochemical study
Retinoblastoma protein expression (pRb) was examined by immunohistochemistry in 37 carcinomas and their respecp16 MTS1/CDK4I in laryngeal carcinomas P Jares et al tive normal tissue. Frozen tissue sections were immunostained using the anti-Rb monoclonal antibody (MoAb) PMG3-245 (PharMingen, San Diego, CA) which recognizes an epitope between amino acids 300 ± 380 of both phosphorylated and unphosphorylated human Rb protein. The anti-Rb MoAb was incubated overnight at 48C at a concentration of 10 mg/ml. The reaction was detected by means of the streptavidin-biotin-alkaline phosphatase (Biogenex, San Ramon, CA) technique using Fast-Red as chromogen. Levamisole was used to inhibit endogenous alkaline phosphatase. The slides were counterstained with hematoxylin (Jares et al., 1996) . Normal squamous epithelium present in all cases was used as positive control. Negative controls included substitution of the primary antibody by a non-related monoclonal antibody and by Phosphate-Buered saline (pH 7.6). Only nuclear staining was evaluated as positive. Similarly to previous studies (Gerardts et al., 1994) , pRb expression was considered negative when either the whole section or extensive areas within the section showed no nuclear staining in the neoplastic cells but de®nite immunoreactivity was observed in the adjacent normal tissue.
Statistical analysis
Categorical data were analysed by means of contingency tables. Probability was calculated with the Fisher's exact test. A logistical regression was performed and the Odds ratios (OR) were calculated by conventional statistical methods. Continuous variables (age) were analysed through analysis of variance for multiple group comparison and Student's t-test for two-groups comparison. Data were analysed using the BMDP statistical package (BMDP Statistical Software, Inc., Los Angeles, CA). Signi®cance was accepted with an a-risk of 0.05.
